Under construction – not a live service
Sign in
Taking people in United StatesPhase 2

Tests a targeted drug combination in adults with returning or resistant aggressive B-cell lymphoma

Tests a combination of targeted drugs in adults with returning aggressive lymphoma.

Key facts

Who runs it
National Cancer Institute (NCI)
Where
Ames, Anaconda, Ankeny, Ashland, Bellevue, Bethesda, Billings, Boone, Bozeman, Brainerd, Buffalo, Burlington, Canton, Carroll, Cedar Rapids, Charlottesville, Chicago, Cincinnati, City of Saint Peters, Cleveland, Clive, Coeur d'Alene, Columbus, Creve Coeur, Crown Point, Danville, Deer River, DeKalb, Derby, Des Moines, Duluth, Durham, Dyer, Effingham, Escanaba, Fargo, Fort Dodge, Geneva, Glenview, Grayslake, Great Falls, Green Bay, Guilford, Hibbing, Hobart, Hood River, Indianapolis, Janesville, Jefferson, Kalispell, La Crosse, Lake Forest, Los Angeles, Madison, Manistique, Marshalltown, Mattoon, Menomonee Falls, Milwaukee, Missoula, Mukwonago, Munster, New Berlin, New Haven, New Orleans, Newberg, Normal, Oak Brook, Oak Creek, Oconomowoc, Oconto Falls, Oklahoma City, Omaha, Oregon City, Orland Park, Philadelphia, Portland, Post Falls, Richmond, Sandpoint, Sandstone, Seattle, Sheboygan, Shiloh, Spooner, St Louis, Sturgeon Bay, Superior, Tucson, Urbana, Valparaiso, Virginia, Warrenville, Waukee, Waukesha, West Bend, and West Chester, United StatesSee the 115 sites
Trial code
Registry title
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
Status
Recruiting
Phase
Phase 2
People taking part
120 people, planned
Started
7 Oct 2025
Expected to end
1 Sept 2028
Type of study
Interventional
Treatments tested
  • Biopsy Procedure
  • Biospecimen Collection
  • Bone Marrow Aspiration
  • Bone Marrow Biopsy
  • Computed Tomography
  • Ibrutinib
  • Lenalidomide
  • Magnetic Resonance Imaging
  • Obinutuzumab
  • Positron Emission Tomography
  • Prednisone
  • Venetoclax
Record updated
9 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults whose aggressive B-cell lymphoma (DLBCL or high-grade B-cell lymphoma) has come back or not responded to earlier treatment. It tests the combination ViPOR.

Age
18 years or older
Sex
All sexes can join
Disease stage
Aggressive B-cell lymphoma that has come back and/or not responded. Cohort 1: CD10-negative DLBCL or similar types. Cohort 2: high-grade B-cell lymphoma with MYC and BCL2 rearrangements. The disease must be measurable.
Earlier treatment
At least 1 earlier treatment with an anthracycline and an anti-CD20 antibody. No more than 3 earlier lines of chemotherapy. No chemotherapy or targeted therapy within 2 weeks before registration. Not more than one of venetoclax, ibrutinib or lenalidomide (or similar drugs) before.
Biomarker or test result
Cohort 1: CD10-negative lymphoma. Cohort 2: MYC and BCL2 rearrangements, with or without BCL6. Enough tumour tissue for lab testing is needed.

Main reasons for not taking part

  • Primary mediastinal large B-cell lymphoma (confirmed or suspected)
  • Primary lymphoma of the central nervous system
  • Pregnancy
  • Active infection at registration
  • Transplant or CAR-T therapy within 3 months before registration

The registry criteria, word for word

Show all 30 criteriaShow less

Who can take part

  • Patient must be ≥ 18 years of age
  • Patient must have histologically or cytologically confirmed aggressive B-cell lymphoma as follows:; Cohort 1: CD10-negative DLBCL, which includes:; CD10-negative non-GCB DLBCL, not otherwise specified (NOS) (i.e., CD10-/BCL6- or CD10-/BCL6+/MUM1+ DLBCL); CD10-negative GCB DLBCL, NOS (i.e., CD10-/BCL6+/MUM1- DLBCL); CD10-negative HGBCL with MYC and BCL6 (without BCL2) translocations (HGBCL-DH-BCL6); CD10-negative HGBCL, NOS (without MYC and BCL2 translocations); CD10-negative T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) OR; Cohort 2: CD10-positive or negative HGBCL with MYC and BCL2 rearrangements (with or without BCL6 rearrangement) (HGBCL-DH-BCL2); NOTE: The site principal investigator must review and verify the pathology report findings to ensure the patient is eligible and is assigned to the respective cohort at the time of registration
  • Patient must have relapsed and/or refractory disease after at least 1 prior anthracycline and anti-CD20 antibody-containing regimen
  • Patient must not have confirmed or suspected primary mediastinal large B-cell lymphoma (PMBL)
  • Patient must not be pregnant due to the potential harm to an unborn fetus with the treatment regimens being used; All patients of childbearing potential must have a serum or urine study with a sensitivity of at least 25 mIU/mL within 14 days prior to registration to rule out pregnancy and again within 24 hours prior to starting cycle 1 day 1 of treatment; A patient of childbearing potential is defined as anyone, regardless of whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
  • Patients of childbearing potential must not expect to conceive children by abstaining from sexual intercourse or by using accepted and effective methods of contraception throughout the entire duration of protocol treatment, including during dose interruptions, and for 6 months after the last dose of protocol treatment. Male patients must not father children by abstaining from sexual intercourse or by using a condom during sexual contact with pregnant partners or partners of childbearing potential throughout the entire duration of protocol treatment, including dose interruptions, and for 6 months after the last dose of protocol treatment even if they have had a successful vasectomy
  • Male patients must agree to not donate semen or sperm during the entire duration of protocol treatment or for at least 28 days after the last dose of lenalidomide
  • Patient must agree to abstain from breastfeeding during the entire duration of protocol treatment and for at least 6 months after the last dose of protocol treatment
  • Patient must agree to abstain from donating blood during the entire duration of protocol treatment and for at least 28 days after the last dose of lenalidomide
  • Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible
  • Absolute neutrophil count (ANC) ≥ 1,000/mcL without requirement for granulocyte colony stimulating factor (G-CSF) support (obtained ≤ 7 days prior to registration)
  • Hemoglobin ≥ 8 g/dL (obtained ≤ 7 days prior to registration)
  • Platelets ≥ 75,000/mcL without requirement for platelet transfusion support (obtained ≤ 7 days prior to registration)
  • Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (or ≤ 3.0 x institutional ULN for patients with documented Gilberts syndrome) (obtained ≤ 7 days prior to registration)
  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) ≤ 3.0 x institutional ULN (obtained ≤ 7 days prior to registration)
  • Creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 30 mL/min/1.73 m\^2 (estimated by Cockcroft-Gault method or measured) (obtained ≤ 7 days prior to registration)
  • Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of registration are eligible for this trial
  • For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
  • Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
  • Patient must not have confirmed or suspected primary DLBCL of the central nervous system (CNS) (PCNSL)
  • Patients with history of secondary CNS lymphoma (SCNSL) are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression
  • Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
  • Patient must not have taken or require warfarin or other strong CYP3A inhibitors or inducers within 7 days prior to registration; NOTE: Antiplatelet agents, other anticoagulants aside from warfarin, as well as mild or moderate CYP3A inhibitors or inducers are permitted on study but should be used with caution
  • Patient must not have an uncontrolled intercurrent illness that would interfere with the safety or efficacy assessment of this protocol
  • Patient must not have evidence of an active infection at the time of registration
  • Patient must not have the following current or prior anti-cancer treatment:; Any chemotherapy, targeted therapy, anti-cancer antibodies, antibody-drug conjugates, or bi-specific antibodies received within 2 weeks prior to registration; NOTE: Short courses of corticosteroids or palliative external beam radiation therapy (XRT) prior to registration are permitted; More than 3 prior lines of cytotoxic chemotherapy, excluding targeted therapy, anti-cancer antibodies, antibody-drug conjugates, bi-specific antibodies, and radio- or toxin-immunoconjugates; NOTE: Cytoreductive chemotherapy followed by autologous stem cell transplant (ASCT) counts as 1 line of cytotoxic therapy. Similarly, cytoreductive chemotherapy (either pre-T-cell collection or as bridging therapy) followed by pre-conditioning therapy/chimeric antigen receptor T-cell (CAR-T) counts as 1 line of therapy, as long as no disease progression occurs between interventions. For both therapies, if progressive disease is documented between 2 distinct regimens, then they should be counted as 2 lines of cytotoxic chemotherapy; Radio- or toxin-immunoconjugates within 10 weeks prior to registration; Previous treatment with more than one of the following study agents: venetoclax (or another BCL2 inhibitor), ibrutinib (or another BTK inhibitor), or lenalidomide (or another immunomodulatory imide drug [IMiD]); Prior autologous stem cell transplant (ASCT), chimeric antigen receptor T-cell (CAR-T) therapy, or allogeneic stem cell (or other organ) transplant within 3 months prior to registration; Any evidence of active graft-versus-host disease or requirement for immunosuppressants within 28 days prior to registration; NOTE: In addition, patient must have recovered (i.e., ≤ grade 1 or baseline) from all adverse events due to previously administered anti-cancer treatment, surgery, or procedure; NOTE: Exceptions to this include events not considered to place the patient at unacceptable risk of participation in the opinion of the treating investigator (i.e., alopecia)
  • Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better
  • Patient must have adequate formalin fixed paraffin embedded (FFPE) tumor tissue specimen from the initial diagnostic biopsy or on-study repeat tumor tissue biopsy for molecular analysis; NOTE: Excisional tumor biopsy is preferred. Core needle biopsies will be considered adequate if there is enough tissue for the mandatory molecular analysis. Submission of an entire FFPE tumor block is preferred, but if unavailable 10 x 10um FFPE scrolls may be submitted as an alternative. If adequate archived FFPE tumor tissue is unavailable, the patient must be willing to undergo research biopsy for molecular analysis
  • Patient must have measurable disease
  • Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status 0-2

Where in United States

  • Mary Greeley Medical CenterAmes, United StatesContact: Joseph J. Merchant (principal investigator)Taking people
  • McFarland Clinic - AmesAmes, United StatesContact: Joseph J. Merchant (principal investigator)Taking people
  • Community Hospital of AnacondaAnaconda, United StatesNo longer taking part
  • UI Health Care Mission Cancer and Blood - Ankeny ClinicAnkeny, United StatesContact: Seema Harichand-Herdt (principal investigator)Taking people
  • Duluth Clinic AshlandAshland, United StatesContact: Bret E. Friday (principal investigator)Taking people
  • Nebraska Medicine-BellevueBellevue, United StatesContact: Snegha Ananth (principal investigator)Taking people
  • National Institutes of Health Clinical CenterBethesda, United StatesContact: Christopher J. Melani (principal investigator)Taking people
  • Walter Reed National Military Medical CenterBethesda, United StatesContact: Christin Destefano (principal investigator)Taking people
  • Billings Clinic Cancer CenterBillings, United StatesContact: John M. Schallenkamp (principal investigator)Taking people
  • McFarland Clinic - BooneBoone, United StatesNo longer taking part
  • Bozeman Health Deaconess HospitalBozeman, United StatesNo longer taking part
  • Essentia Health Saint Joseph's Medical CenterBrainerd, United StatesContact: Bret E. Friday (principal investigator)Taking people
  • Roswell Park Cancer InstituteBuffalo, United StatesContact: Alex Niu (principal investigator)Taking people
  • University of Vermont and State Agricultural CollegeBurlington, United StatesContact: James N. Gerson (principal investigator)Taking people
  • University of Vermont Medical CenterBurlington, United StatesContact: James N. Gerson (principal investigator)Taking people
  • Aultman Health FoundationCanton, United StatesContact: Aarthi Rajkumar (principal investigator)Taking people
  • Saint Anthony Regional HospitalCarroll, United StatesContact: Seema Harichand-Herdt (principal investigator)Taking people
  • Mercy HospitalCedar Rapids, United StatesContact: Deborah W. Wilbur (principal investigator)Taking people
  • Oncology Associates at Mercy Medical CenterCedar Rapids, United StatesContact: Deborah W. Wilbur (principal investigator)Taking people
  • University of Virginia Cancer CenterCharlottesville, United StatesContact: Craig A. Portell (principal investigator)Taking people
  • Northwestern UniversityChicago, United StatesContact: Reem Karmali (principal investigator)Taking people
  • University of Cincinnati Cancer Center-UC Medical CenterCincinnati, United StatesContact: Tahir Latif (principal investigator)Taking people
  • Siteman Cancer Center at Saint Peters HospitalCity of Saint Peters, United StatesContact: Brad S. Kahl (principal investigator)Taking people
  • Case Western Reserve UniversityCleveland, United StatesContact: Ali W. Bseiso (principal investigator)Taking people
  • UI Health Care Mission Cancer and Blood - West Des Moines ClinicClive, United StatesContact: Seema Harichand-Herdt (principal investigator)Taking people
  • Kootenai Health - Coeur d'AleneCoeur d'Alene, United StatesContact: John M. Schallenkamp (principal investigator)Taking people
  • Ohio State University Comprehensive Cancer CenterColumbus, United StatesContact: Kathryn Lurain (principal investigator)Taking people
  • Siteman Cancer Center at West County HospitalCreve Coeur, United StatesContact: Brad S. Kahl (principal investigator)Taking people
  • Northwest Cancer Center - Crown PointCrown Point, United StatesContact: Suparna Mantha (principal investigator)Taking people
  • Carle at The RiverfrontDanville, United StatesNo longer taking part
  • Essentia Health - Deer River ClinicDeer River, United StatesContact: Bret E. Friday (principal investigator)Taking people
  • Northwestern Medicine Cancer Center KishwaukeeDeKalb, United StatesContact: Reem Karmali (principal investigator)Taking people
  • Smilow Cancer Hospital-Derby Care CenterDerby, United StatesContact: Shalin Kothari (principal investigator)Taking people
  • Broadlawns Medical CenterDes Moines, United StatesContact: Seema Harichand-Herdt (principal investigator)Taking people
  • Iowa Methodist Medical CenterDes Moines, United StatesContact: Seema Harichand-Herdt (principal investigator)Taking people
  • UI Health Care Mission Cancer and Blood - Des Moines ClinicDes Moines, United StatesContact: Seema Harichand-Herdt (principal investigator)Taking people
  • UI Health Care Mission Cancer and Blood - Laurel ClinicDes Moines, United StatesContact: Seema Harichand-Herdt (principal investigator)Taking people
  • Essentia Health Cancer CenterDuluth, United StatesContact: Bret E. Friday (principal investigator)Taking people
  • Duke University Medical CenterDurham, United StatesNo longer taking part
  • Northwest Oncology LLCDyer, United StatesContact: Suparna Mantha (principal investigator)Taking people
  • Carle Physician Group-EffinghamEffingham, United StatesNo longer taking part
  • OSF Saint Francis Hospital and Medical GroupEscanaba, United StatesContact: Brian L. Burnette (principal investigator)Taking people
  • Essentia Health Cancer Center-South University ClinicFargo, United StatesContact: Bret E. Friday (principal investigator)Taking people
  • McFarland Clinic - Trinity Cancer CenterFort Dodge, United StatesContact: Joseph J. Merchant (principal investigator)Taking people
  • UI Healthcare Mission Cancer and Blood - Fort DodgeFort Dodge, United StatesContact: Seema Harichand-Herdt (principal investigator)Taking people
  • Northwestern Medicine Cancer Center DelnorGeneva, United StatesContact: Reem Karmali (principal investigator)Taking people
  • Northwestern Medicine Glenview Outpatient CenterGlenview, United StatesContact: Reem Karmali (principal investigator)Taking people
  • Northwestern Medicine Grayslake Outpatient CenterGrayslake, United StatesContact: Reem Karmali (principal investigator)Taking people
  • Benefis Sletten Cancer InstituteGreat Falls, United StatesContact: John M. Schallenkamp (principal investigator)Taking people
  • Saint Vincent Hospital Cancer Center at Saint Mary'sGreen Bay, United StatesContact: Brian L. Burnette (principal investigator)Taking people
  • Saint Vincent Hospital Cancer Center Green BayGreen Bay, United StatesContact: Brian L. Burnette (principal investigator)Taking people
  • Smilow Cancer Hospital Care Center - GuilfordGuilford, United StatesContact: Shalin Kothari (principal investigator)Taking people
  • Essentia Health Hibbing ClinicHibbing, United StatesContact: Bret E. Friday (principal investigator)Taking people
  • Saint Mary Medical CenterHobart, United StatesContact: Suparna Mantha (principal investigator)Taking people
  • Providence Hood River Memorial HospitalHood River, United StatesContact: Alison K. Conlin (principal investigator)Taking people
  • Saint Catherine HospitalIndianapolis, United StatesContact: Suparna Mantha (principal investigator)Taking people
  • Mercyhealth Hospital and Cancer Center - JanesvilleJanesville, United StatesContact: Emily G. Robinson (principal investigator)Taking people
  • McFarland Clinic - JeffersonJefferson, United StatesNo longer taking part
  • Logan Health Medical CenterKalispell, United StatesNo longer taking part
  • Gundersen Lutheran Medical CenterLa Crosse, United StatesContact: Kurt Oettel (principal investigator)Taking people
  • Northwestern Medicine Lake Forest HospitalLake Forest, United StatesContact: Reem Karmali (principal investigator)Taking people
  • Cedars-Sinai Medical CenterLos Angeles, United StatesContact: Justin M. Darrah (principal investigator)Taking people
  • University of Wisconsin Carbone Cancer Center - Eastpark Medical CenterMadison, United StatesContact: Priyanka Pophali (principal investigator)Taking people
  • University of Wisconsin Carbone Cancer Center - University HospitalMadison, United StatesContact: Priyanka Pophali (principal investigator)Taking people
  • Schoolcraft Memorial HospitalManistique, United StatesContact: Brian L. Burnette (principal investigator)Taking people
  • McFarland Clinic - MarshalltownMarshalltown, United StatesContact: Joseph J. Merchant (principal investigator)Taking people
  • Carle Physician Group-Mattoon/CharlestonMattoon, United StatesNo longer taking part
  • Froedtert Menomonee Falls HospitalMenomonee Falls, United StatesContact: Kaitlin Annunzio (principal investigator)Taking people
  • Medical College of WisconsinMilwaukee, United StatesContact: Kaitlin Annunzio (principal investigator)Taking people
  • Community Medical CenterMissoula, United StatesContact: John M. Schallenkamp (principal investigator)Taking people
  • ProHealth D N Greenwald CenterMukwonago, United StatesContact: Timothy R. Wassenaar (principal investigator)Taking people
  • The Community HospitalMunster, United StatesContact: Suparna Mantha (principal investigator)Taking people
  • Women's Diagnostic Center - MunsterMunster, United StatesContact: Suparna Mantha (principal investigator)Taking people
  • Froedtert and MCW Moorland Reserve Health CenterNew Berlin, United StatesContact: Kaitlin Annunzio (principal investigator)Taking people
  • Yale UniversityNew Haven, United StatesContact: Shalin Kothari (principal investigator)Taking people
  • Ochsner Medical Center JeffersonNew Orleans, United StatesNo longer taking part
  • Providence Newberg Medical CenterNewberg, United StatesContact: Alison K. Conlin (principal investigator)Taking people
  • Carle BroMenn Medical CenterNormal, United StatesNo longer taking part
  • Carle Cancer Institute NormalNormal, United StatesNo longer taking part
  • Northwestern Medicine Oak BrookOak Brook, United StatesContact: Reem Karmali (principal investigator)Taking people
  • Drexel Town Square Health CenterOak Creek, United StatesContact: Kaitlin Annunzio (principal investigator)Taking people
  • ProHealth Oconomowoc Memorial HospitalOconomowoc, United StatesContact: Timothy R. Wassenaar (principal investigator)Taking people
  • Saint Vincent Hospital Cancer Center at Oconto FallsOconto Falls, United StatesContact: Brian L. Burnette (principal investigator)Taking people
  • University of Oklahoma Health Sciences CenterOklahoma City, United StatesNo longer taking part
  • Nebraska Medicine-Village PointeOmaha, United StatesContact: Snegha Ananth (principal investigator)Taking people
  • University of Nebraska Medical CenterOmaha, United StatesContact: Snegha Ananth (principal investigator)Taking people
  • Providence Willamette Falls Medical CenterOregon City, United StatesContact: Alison K. Conlin (principal investigator)Taking people
  • Northwestern Medicine Orland ParkOrland Park, United StatesContact: Reem Karmali (principal investigator)Taking people
  • Thomas Jefferson University HospitalPhiladelphia, United StatesContact: Ubaldo E. Martinez Outschoorn (principal investigator)Taking people
  • Providence Portland Medical CenterPortland, United StatesContact: Alison K. Conlin (principal investigator)Taking people
  • Providence Saint Vincent Medical CenterPortland, United StatesContact: Alison K. Conlin (principal investigator)Taking people
  • Kootenai Clinic Cancer Services - Post FallsPost Falls, United StatesContact: John M. Schallenkamp (principal investigator)Taking people
  • VCU Massey Comprehensive Cancer CenterRichmond, United StatesContact: Bruce O. Hough (principal investigator)Taking people
  • Kootenai Clinic Cancer Services - SandpointSandpoint, United StatesContact: John M. Schallenkamp (principal investigator)Taking people
  • Essentia Health SandstoneSandstone, United StatesContact: Bret E. Friday (principal investigator)Taking people
  • Swedish Medical Center-First HillSeattle, United StatesContact: Alison K. Conlin (principal investigator)Taking people
  • Saint Vincent Hospital Cancer Center at SheboyganSheboygan, United StatesContact: Brian L. Burnette (principal investigator)Taking people
  • Sheboygan Physicians GroupSheboygan, United StatesContact: Brian L. Burnette (principal investigator)Taking people
  • Memorial Hospital EastShiloh, United StatesContact: Brad S. Kahl (principal investigator)Taking people
  • Essentia Health-Spooner ClinicSpooner, United StatesContact: Bret E. Friday (principal investigator)Taking people
  • Siteman Cancer Center at Christian HospitalSt Louis, United StatesContact: Brad S. Kahl (principal investigator)Taking people
  • Siteman Cancer Center-South CountySt Louis, United StatesContact: Brad S. Kahl (principal investigator)Taking people
  • Washington University School of MedicineSt Louis, United StatesContact: Brad S. Kahl (principal investigator)Taking people
  • Saint Vincent Hospital Cancer Center at Sturgeon BaySturgeon Bay, United StatesContact: Brian L. Burnette (principal investigator)Taking people
  • Essentia Health Saint Mary's Hospital - SuperiorSuperior, United StatesContact: Bret E. Friday (principal investigator)Taking people
  • Banner University Medical Center - TucsonTucson, United StatesNo longer taking part
  • University of Arizona Cancer Center-North CampusTucson, United StatesNo longer taking part
  • Carle Cancer CenterUrbana, United StatesNo longer taking part
  • Northwest Cancer Center - ValparaisoValparaiso, United StatesContact: Suparna Mantha (principal investigator)Taking people
  • Essentia Health Virginia ClinicVirginia, United StatesContact: Bret E. Friday (principal investigator)Taking people
  • Northwestern Medicine Cancer Center WarrenvilleWarrenville, United StatesContact: Reem Karmali (principal investigator)Taking people
  • UI Health Care Mission Cancer and Blood - Waukee ClinicWaukee, United StatesContact: Seema Harichand-Herdt (principal investigator)Taking people
  • UW Cancer Center at ProHealth CareWaukesha, United StatesContact: Timothy R. Wassenaar (principal investigator)Taking people
  • Froedtert West Bend Hospital/Kraemer Cancer CenterWest Bend, United StatesContact: Kaitlin Annunzio (principal investigator)Taking people
  • University of Cincinnati Cancer Center-West ChesterWest Chester, United StatesContact: Tahir Latif (principal investigator)Taking people

About the trial

What the trial wants to find out

This phase II trial tests how well venetoclax, ibrutinib, prednisone, obinutuzumab, and Revlimid® (ViPOR) works in treating patients with CD10 negative diffuse large B-cell lymphoma (DLBCL) and high-grade lymphoma with MYC and BCL2 rearrangements that has come back after a period of improvement (relapsed) and/or that has not responded to previous treatment (refractory). Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Ibrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cell (a type of white blood cells) cancers at abnormal levels. This may help keep cancer cells from growing and spreading. Anti-inflammatory drugs, such as prednisone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Obinutuzumab, a monoclonal antibody, binds to a protein called CD20, which is found on B cells and some types of leukemia and lymphoma cells. Obinutuzumab may block CD20 and help the immune system kill cancer cells. Revlimid, a type of anti-angiogenesis agent and a type of immunomodulating agent, may help the immune system kill abnormal blood cells or cancer cells. It may also prevent the growth of new blood vessels that cancers need to grow. ViPOR may be an effective treatment option for patients with relapsed and/or refractory CD10 negative DLBCL and high-grade B-cell lymphoma with MYC and BCL2 rearrangements.

The group in the trial

  • Treatment (ViPOR)Treatment being tested

    Patients receive venetoclax PO QD on days 2-14, ibrutinib PO QD on days 1-14, prednisone PO QD on days 1-7, obinutuzumab IV on days 1 and 2, and Revlimid PO QD on days 1-14 of each cycle. Cycles repeat every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection, PET, CT and/or MRI and optional tumor biopsy and bone marrow aspiration and biopsy throughout the study.

    Treatment: Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Ibrutinib, Lenalidomide, Magnetic Resonance Imaging, Obinutuzumab, Positron Emission Tomography, Prednisone, and Venetoclax

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Phase II Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed or Refractory CD10-Negative Diffuse Large B-Cell Lymphoma (DLBCL) and High-Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements (HGBCL-DH-BCL2)
Plain-language title
Tests a targeted drug combination in adults with returning or resistant aggressive B-cell lymphomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
9 November 2026